(NASDAQ: ACRS) Aclaris Therapeutics's forecast annual revenue growth rate of -16.17% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.44%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.67%.
Aclaris Therapeutics's revenue in 2025 is $15,742,000.On average, 9 Wall Street analysts forecast ACRS's revenue for 2025 to be $935,669,484, with the lowest ACRS revenue forecast at $796,337,507, and the highest ACRS revenue forecast at $1,118,339,557. On average, 9 Wall Street analysts forecast ACRS's revenue for 2026 to be $992,334,044, with the lowest ACRS revenue forecast at $424,713,337, and the highest ACRS revenue forecast at $1,501,231,632.
In 2027, ACRS is forecast to generate $991,683,973 in revenue, with the lowest revenue forecast at $424,713,337 and the highest revenue forecast at $1,501,231,632.